| Perinatal morbidity and mortality in early‐onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE) C Lees, N Marlow, B Arabin, CM Bilardo, C Brezinka, JB Derks, J Duvekot, ... Ultrasound in obstetrics & gynecology 42 (4), 400-408, 2013 | 800* | 2013 |
| Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases NS Vermeer, SMJM Straus, AK Mantel-Teeuwisse, F Domergue, ... Drug safety 36, 617-625, 2013 | 82 | 2013 |
| Traceability of biologicals: present challenges in pharmacovigilance NS Vermeer, I Spierings, AK Mantel-Teeuwisse, SMJM Straus, TJ Giezen, ... Expert Opinion on Drug Safety 14 (1), 63-72, 2015 | 66 | 2015 |
| Utilization of evidence‐based therapy for the secondary prevention of acute coronary syndromes in Australian practice NS Vermeer, BV Bajorek Journal of clinical pharmacy and therapeutics 33 (6), 591-601, 2008 | 43 | 2008 |
| Traceability of biologics in The Netherlands: an analysis of information-recording systems in clinical practice and spontaneous ADR reports K Klein, JHG Scholl, NS Vermeer, AW Broekmans, EP Van Puijenbroek, ... Drug Safety 39, 185-192, 2016 | 40 | 2016 |
| Risk management plans as a tool for proactive pharmacovigilance: a cohort study of newly approved drugs in Europe NS Vermeer, RG Duijnhoven, S Straus, AK Mantel‐Teeuwisse, PR Arlett, ... Clinical Pharmacology & Therapeutics 96 (6), 723-731, 2014 | 36 | 2014 |
| Identifiability of biologicals in adverse drug reaction reports received from European clinical practice NS Vermeer, TJ Giezen, S Zastavnik, E Wolff‐Holz, A Hidalgo‐Simon Clinical Pharmacology & Therapeutics 105 (4), 962-969, 2019 | 34 | 2019 |
| Drug‐induced progressive multifocal leukoencephalopathy: lessons learned from contrasting natalizumab and rituximab NS Vermeer, S Straus, AK Mantel‐Teeuwisse, A Hidalgo‐Simon, ... Clinical Pharmacology & Therapeutics 98 (5), 542-550, 2015 | 26 | 2015 |
| The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product‐specific risks for biologicals: a simulation study NS Vermeer, HC Ebbers, SMJM Straus, HGM Leufkens, TCG Egberts, ... pharmacoepidemiology and drug safety 25 (3), 297-306, 2016 | 13 | 2016 |
| Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: an observational study EA Basak, NS Vermeer, K de Joode, DP Hurkmans, DEM Velthuis, ... European Journal of Cancer 174, 113-120, 2022 | 11 | 2022 |
| Strategy in Regulatory Decision‐Making for Management of Progressive Multifocal Leukoencephalopathy A Segec, B Keller‐Stanislawski, NS Vermeer, C Macchiarulo, SM Straus, ... Clinical Pharmacology & Therapeutics 98 (5), 502-505, 2015 | 6 | 2015 |
| Harmful Effects of Proton Pump Inhibitors: Discrepancies Between Observational Studies and Randomized Clinical Trials—Reply M Maggio, A Corsonello JAMA Internal Medicine 173 (16), 1559-1560, 2013 | 6 | 2013 |
| Sparse Batch Number Reporting for Biologicals in FDA's Adverse Event Reporting System (AERS) NS Vermeer, SM Straus, AK Teeuwisse, TC Egberts, HG Leufkens, ... DRUG SAFETY 34 (10), 1002-1002, 2011 | 1 | 2011 |
| 1863P Incidence and predictors of severe adverse events during anti-PD-1 treatment EA Basak, NS Vermeer, KD Joode, DP Hurkmans, DEM Velthuis, ... Annals of Oncology 32, S1251-S1252, 2021 | | 2021 |
| 2.2 Traceability of biologics in the K Klein, JHG Scholl, NS Vermeer, AW Broekmans, EP van Puijenbroek, ... edicines 39, 43, 2016 | | 2016 |
| Pharmacovigilance of biologicals: dynamics in post-approval safety learning NS Vermeer Utrecht University, 2015 | | 2015 |
| 3.2 The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals NS Vermeer, HC Ebbers, S Straus, HGM Leufkens, ACG Egberts, ... Pharmacovigilance of biologicals, 75, 2015 | | 2015 |
| 4.2 Cancer risks of medicines approved in the European Union: what is known at licensing and what is solved post-marketing? RG Duijnhoven, NS Vermeer, S Straus, AW Hoes, AT de Boer, ... Pharmacovigilance of biologicals, 133, 2015 | | 2015 |
| 3.1 Traceability of biopharmaceuticals in spontaneous reporting systems: sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases NS Vermeer, S Straus, AK Mantel-Teeuwisse, F Domergue, ACG Egberts, ... Pharmacovigilance of biologicals 36, 57, 2015 | | 2015 |
| 2.2 Analytical interference by monoclonal antibodies in frequently used immunoassays: an in vitro study NS Vermeer, ML De Bruin, ACG Egberts, WW van Solinge, E Lentjes Pharmacovigilance of biologicals, 43, 2015 | | 2015 |
